---
title: "KLOW (GHK-Cu / KPV / BPC-157 / TB-500)"
canonical_url: https://peptidelibrary.app/library/klow
description: "Vendor regenerative blend (commonly BPC-157, TB-500, GHK-Cu, and KPV). Not a single drug; several components are WADA-prohibited or unapproved."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# KLOW (GHK-Cu / KPV / BPC-157 / TB-500)

KLOW (GHK-Cu / KPV / BPC-157 / TB-500), also called KLOW blend or BPC-157 + TB-500 + GHK-Cu + KPV, is a regenerative blend in the Multi-Mechanism Repair class. KLOW is a compounded blend of GHK-Cu, KPV, BPC-157 and TB-500, marketed for tissue repair.

Vendor regenerative blend (commonly BPC-157, TB-500, GHK-Cu, and KPV). Not a single drug; several components are WADA-prohibited or unapproved.

Also known as: KLOW blend, BPC-157 + TB-500 + GHK-Cu + KPV.

Categories: Muscle/Recovery, Cosmetic, Experimental.

## Classification

- Type: Regenerative blend
- Mechanism class: Multi-Mechanism Repair
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

KLOW is a compounded blend of GHK-Cu, KPV, BPC-157 and TB-500, marketed for tissue repair. The components act on separate proposed pathways: GHK-Cu on copper-dependent matrix remodelling and collagen synthesis; KPV, the C-terminal tripeptide of alpha-MSH, on NF-kB-mediated inflammatory signalling; BPC-157 on angiogenic and nitric oxide pathways in animal models; and TB-500 on actin sequestration and cell migration. As with any such blend, the combination has no mechanism beyond its parts, no pivotal trial exists for the product, and the pharmacokinetics of co-administration have not been studied. Every component is unapproved.

Targets: Multiple (component-dependent).

Origin: Commercial peptide blend.

## Properties

- Sequence: GHK-Cu: Gly-His-Lys-Cu; KPV: Lys-Pro-Val; BPC-157: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val; TB-500: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH (thymosin β4 17–23 fragment, as TB-500 is usually sold; some vendors supply full-length thymosin β4)
- Molecular formula: Varies
- Molecular weight: Varies
- Half-life: Varies

## Evidence

- Evidence level: Insufficient Evidence
- Highest documented: Lab & animal studies
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 1
- Latest source: 2026

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Miller TR et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006. 2006. Human study (early or uncontrolled). Population: Patients after circumoral CO2 laser skin resurfacing (13 completed). No significant difference in erythema, wrinkles or skin quality on objective or blinded evaluation; patient-rated satisfaction was higher with GHK-Cu. Research on a related compound, not this one. Limitations: Studied an analog, not KLOW (GHK-Cu / KPV / BPC-157 / TB-500) itself [Source](https://pubmed.ncbi.nlm.nih.gov/16847171/)
2. NCT07437547 — BPC 157 for Acute Hamstring Muscle Strain Repair. Human study (early or uncontrolled). Population: Adults with acute hamstring muscle strain (planned n=120). Hamstring muscle strain repair; no results posted. Research on a related compound, not this one. Limitations: Studied an analog, not KLOW (GHK-Cu / KPV / BPC-157 / TB-500) itself; Registered trial with no published results yet. [Source](https://clinicaltrials.gov/study/NCT07437547)
3. NCT07487363 — TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD. Human study (early or uncontrolled). Population: Adults with stable atherosclerotic cardiovascular disease (planned n=80). Cardiovascular biomarkers; no results posted. Research on a related compound, not this one. Limitations: Studied an analog, not KLOW (GHK-Cu / KPV / BPC-157 / TB-500) itself; Registered trial with no published results yet. [Source](https://clinicaltrials.gov/study/NCT07487363)
4. A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon. Acta Biomater. 2022. 2022. Preclinical: animal or lab study. Population: Rats with TNBS-induced colitis. Better relief of colitis and recovery of the colon's epithelial barrier with the hydrogel-bound KPV. Research on a related compound, not this one. Limitations: Studied an analog, not KLOW (GHK-Cu / KPV / BPC-157 / TB-500) itself; Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/35245681/)
5. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026. 2026. Preclinical: animal or lab study. Population: Male Sprague-Dawley rats after Achilles tendon transection and repair (n=32, 8 per group). Both peptides alone improved tendon histology, and TB-500 alone improved load to failure; the combination gave no added benefit over either alone. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/42542926/)

### Registered trials

- [NCT07437547](https://clinicaltrials.gov/study/NCT07437547)
- [NCT07487363](https://clinicaltrials.gov/study/NCT07487363)

## Safety

Side effects: Irritation; Nausea.

Risks: Copper imbalance; Limited blend data.

Contraindications: Copper allergy.

Human safety basis: No controlled human safety data

Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

KLOW (GHK-Cu / KPV / BPC-157 / TB-500) is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- Availability: Research-Only

## Frequently asked questions

### What is KLOW (GHK-Cu / KPV / BPC-157 / TB-500)?

Vendor regenerative blend (commonly BPC-157, TB-500, GHK-Cu, and KPV). Not a single drug; several components are WADA-prohibited or unapproved.

### How does KLOW (GHK-Cu / KPV / BPC-157 / TB-500) work?

KLOW is a compounded blend of GHK-Cu, KPV, BPC-157 and TB-500, marketed for tissue repair. The components act on separate proposed pathways: GHK-Cu on copper-dependent matrix remodelling and collagen synthesis; KPV, the C-terminal tripeptide of alpha-MSH, on NF-kB-mediated inflammatory signalling; BPC-157 on angiogenic and nitric oxide pathways in animal models; and TB-500 on actin sequestration and cell migration.

### Is KLOW (GHK-Cu / KPV / BPC-157 / TB-500) FDA approved?

No. KLOW (GHK-Cu / KPV / BPC-157 / TB-500) is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the half-life of KLOW (GHK-Cu / KPV / BPC-157 / TB-500)?

Reported half-life for KLOW (GHK-Cu / KPV / BPC-157 / TB-500) is Varies. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### What is the amino acid sequence of KLOW (GHK-Cu / KPV / BPC-157 / TB-500)?

KLOW is a blend, not a single peptide. Its components are GHK-Cu (Gly-His-Lys copper complex), KPV (Lys-Pro-Val), BPC-157 (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) and TB-500, which is usually the acetylated thymosin β4 fragment Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln rather than the full 43-residue protein. There is no single molecular formula; composition depends on the vial.

### What peptides are similar to KLOW (GHK-Cu / KPV / BPC-157 / TB-500)?

Compounds most often compared with KLOW (GHK-Cu / KPV / BPC-157 / TB-500) include GHK-Cu (Copper Peptide), KPV, BPC-157 and TB-500 (Thymosin Beta-4 fragment). They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [WADA Prohibited List 2026](https://www.wada-ama.org/en/prohibited-list)
- [Component evidence (GHK-Cu (Copper Peptide)) — Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes?](https://pubmed.ncbi.nlm.nih.gov/39795193/)
- [Component evidence (GHK-Cu (Copper Peptide)) — Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data](https://pubmed.ncbi.nlm.nih.gov/29986520/)
- [Component evidence (KPV) — A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon](https://pubmed.ncbi.nlm.nih.gov/35245681/)
- [Component evidence (KPV) — Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats](https://pubmed.ncbi.nlm.nih.gov/34547895/)
